Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16877906 | 1.00 | HIF1A (0.33) | HIF1AMAPTPDE4AKDR | |
| Hydrochloric Acid SCHEMBL4827298 | 0.97 | HIF1A (0.32) | HIF1AMAPTPDE4AKDR | |
| SCHEMBL16878051 | 0.94 | HIF1A (0.33) | HIF1AMAPTPDE4AKDR | |
| SCHEMBL5428826 | 0.92 | HTR2A (0.30) | — | |
| SCHEMBL6012363 | 0.91 | CXCR4 (0.35) | — | |
| SCHEMBL16877841 | 0.89 | HIF1A (0.33) | HIF1AMAPTPDE4AKDR | |
| SCHEMBL1796614 | 0.88 | — | — | |
| SCHEMBL21538620 | 0.88 | — | — | |
| SCHEMBL336284 | 0.88 | — | — | |
| Phosphine SCHEMBL22689841 | 0.86 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 102 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8680092-B2 | Nitrogenous heterocyclic compound and medicinal use thereof | ONO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-25 | — | — | US | claimed |
| EP-4143235-A1 | METHODS AND COMPOSITIONS FOR TREATING CYTOKINE STORM INFECTIONS, INCLUDING COVID-19, BY INHIBITING CCR5/CCL5 INTERACTION | IncellDx, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-111285875-B | Heterocyclic compound, application thereof and pharmaceutical composition containing same | 苏州信诺维医药科技股份有限公司 | 2023-02-03 | — | — | CN | disclosed |
| EP-3397627-B1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2022-01-26 | — | — | EP | disclosed |
| EP-3224248-B1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO LTD (CN) | 2021-05-05 | — | — | EP | disclosed |
| US-10894038-B2 | Indolizine derivatives, composition and methods of use | SHANGHAI FOCHON PHARMACEUTICAL CO. LTD. (CN) | 2021-01-19 | — | — | US | disclosed |
| US-20200113876-A1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | FOCHON PHARMACEUTICALS, LTD. (CN) | 2020-04-16 | — | — | US | disclosed |
| EP-2883865-B1 | Compound capable of binding S1P receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO (JP) | 2019-09-25 | — | — | EP | disclosed |
| US-10328060-B2 | Certain protein kinase inhibitors | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2019-06-25 | — | — | US | disclosed |
| US-20180036293-A1 | CERTAIN PROTEIN KINASE INHIBITORS | SHANGHAI FOCHON PHARMACEUTICAL CO., LTD. (CN) | 2018-02-08 | — | — | US | disclosed |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | ONO PHARMACEUTICAL CO., LTD (JP) | 2007-07-19 | — | — | US | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1790639-A1 | COMPOUND CONTAINING BASIC GROUP AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-05-30 | — | — | EP | disclosed |
| EP-1760071-A1 | COMPOUND HAVING S1P RECEPTOR BINDING POTENCY AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-03-07 | — | — | EP | disclosed |
| EP-1739081-A1 | HYDRAZINO-SUBSTITUTED HETEROCYCLIC NITRILE COMPOUNDS AND USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2007-01-03 | — | — | EP | disclosed |
| EP-1724264-A1 | NITRILES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-11-22 | — | — | EP | disclosed |
| US-7119091-B2 | Triazaspiro[5.5]undecane derivatives and pharmaceutical compositions comprising thereof, as an active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-10-10 | — | — | US | disclosed |
| EP-1661881-A2 | COMPOUND CAPABLE OF BINDING S1P RECEPTOR AND PHARMACEUTICAL USE THEREOF | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-05-31 | — | — | EP | disclosed |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | ONO PHARMACEUTICAL CO., LTD. (JP) | 2006-01-26 | — | — | US | disclosed |
| US-6288061-B1 | INTERLEUKIN INHIBITORS; ASTHMA, BRONCHODILATOR AGENTS, ANTIALLERGENS | WELFIDE CORPORATION (JP) | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180036293-A1 | CERTAIN PROTEIN KINASE INHIBITORS | AKT1, PIK3CA, AKT3 | HIF1A 1575/4885MAPT 2101/4885PDE4A 1112/4885 |
| US-20070167425-A1 | Compound capable of binding s1p receptor and pharmaceutical use thereof | S1PR1, S1PR3, S1PR2 | HIF1A 2986/4885MAPT 4603/4885PDE4A 1025/4885 |
| US-10328060-B2 | Certain protein kinase inhibitors | AKT1, PIK3CA, AKT3 | HIF1A 1575/4885MAPT 2101/4885PDE4A 1112/4885 |
| US-20200113876-A1 | INDOLIZINE DERIVATIVES, COMPOSITION AND METHODS OF USE | INMT, SLC14A1, AADAT | HIF1A 3729/4885MAPT 258/4885PDE4A 2997/4885 |
| US-10894038-B2 | Indolizine derivatives, composition and methods of use | INMT, SLC14A1, AADAT | HIF1A 3729/4885MAPT 258/4885PDE4A 2997/4885 |
| US-20060019977-A1 | Spiroheterocyclic derivative compounds and drugs comprising the compound as the active ingredient | CCR1, ACKR3, CCR10 | HIF1A 662/4885MAPT 4623/4885PDE4A 3040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.